MarketBeat
13 Nov 2026, 05:15 UTC · 59m ago
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
Impact · against what's priced in
Relmada Therapeutics (RLMD) provides a positive outlook driven by strong efficacy data for NDV-01 and a cash runway extending to 2029. The clear regulatory timeline for year-end 2026 filings and the potential for Phase III enrollment in Q1 2027 serve as near-term catalysts.
- RLMD+0.50
No priced-in read yet
- In context
The company reports 86% complete response rates at 18 months for high-risk patients in the NDV-01 Phase II study and a cash position of $202.1 million that funds operations through 2029.
Read from the article alone
